Detalhe da pesquisa
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163621
2.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048786
3.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363867
4.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37172204
5.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108374
6.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693677
7.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Ann Hematol
; 102(10): 2741-2752, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592092
8.
[Further Development and Interoperability in Oncological Care Structures, Quality Control and Research]. / Weiterentwicklung und Vernetzung der onkologischen Versorgungsstrukturen, der Qualitätssicherung und der Forschung.
Gesundheitswesen
; 85(7): 649-656, 2023 Jul.
Artigo
em Alemão
| MEDLINE | ID: mdl-36328158
9.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
10.
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Haematologica
; 104(6): 1202-1208, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573503
11.
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
N Engl J Med
; 370(12): 1101-10, 2014 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24401022
12.
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Am J Hematol
; 96(10): E383-E386, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161627
13.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol
; 16(16): 1691-9, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26549589
14.
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Breast Cancer Res Treat
; 149(1): 141-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25519041
15.
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Haematologica
; 105(5): 1465, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32358081
16.
MiR-134-mediated ß1 integrin expression and function in mesenchymal stem cells.
Biochim Biophys Acta
; 1833(12): 3396-3404, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24135056
17.
MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells.
Haematologica
; 99(6): 997-1005, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24584347
18.
Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trial.
Neoplasia
; 49: 100953, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38232493
19.
MicroRNA29a regulates the expression of the nuclear oncogene Ski.
Blood
; 118(7): 1899-902, 2011 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21685371
20.
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
J Clin Oncol
; 40(33): 3800-3807, 2022 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998303